Gilead's HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress.

Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line.

Barrons • an hour ago

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade

Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.

Investors Business Daily • an hour ago

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength

The biopharmaceutical company said it now expects full-year product sales of $31 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.

WSJ • an hour ago

Gilead Sciences Announces Third Quarter 2026 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026. “Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “Our performance enabled us to raise our full year base business revenue guidance again this qua.

Business Wire • an hour ago

3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead

Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast.

24/7 Wall Street • Oct 28, 2026

Gilead to Report Q3 Earnings: How Should You Play the Stock Now?

Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.

Zacks Investment Research • Oct 27, 2026

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.

Zacks Investment Research • Oct 27, 2026

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.

Zacks Investment Research • Oct 26, 2026

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

Amgen and Gilead pay forward dividend yields above 2%. Gilead has a lower dividend payout ratio, but Amgen is generating stronger sales growth.

The Motley Fool • Oct 25, 2026

The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme

HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors' medications. In many cases, these presc.

Business Wire • Oct 23, 2026